X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Glycotope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 11, 2023
Details:
Evotec will provide IAMA with preclinical and clinical services to support the anticipated Phase 1 clinical trial to investigate IAMA's lead program IAMA-6, a small molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy.
Lead Product(s): IAMA-6
Therapeutic Area: Neurology Product Name: IAMA-6
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: IAMA Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 02, 2023
Details:
The collaboration aims to accelerate the translation of academic ideas to therapeutic product candidates in the cardiometabolic space through LAB eN² that combines Evotec's multimodality drug discovery and preclinical development capabilities.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 26, 2023
Details:
Under the licence agreement, Bristol Myers Squibb has selected an undisclosed number of programmes that were rapidly developed and progressed using Evotec's precision medicine platforms for further development within the expanded collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $4,000.0 million Upfront Cash: $50.0 million
Deal Type: Expanded Collaboration July 11, 2023
Details:
Under the agreement, Evotec Biologics will develop drug product prototypes of new monoclonal antibodies (mAbs) using AI-driven de novo antibody design through the execution of Phase I first-in human clinical trials.
Lead Product(s): Monoclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $74.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 05, 2023
Details:
The partnership aims for the development of multiple clinical candidates including, BAY401016, a mAb targeting the protein Semaphorin-3A, is being developed in phase I study as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease.
Lead Product(s): BAY401016
Therapeutic Area: Genetic Disease Product Name: BAY401016
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $351.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2023
Details:
The funding will support the discovery and development of RNA-targeting small molecules by leveraging its rSM platform for potential first-in-class therapeutics against Henipaviruses.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Open Philanthropy
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding June 02, 2023
Details:
Under the expanded collaboration, the companies will develop the pipeline of molecular glue degraders. The companies will leverage all of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development platforms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $5,200.0 million Upfront Cash: $200.0 million
Deal Type: Expanded Collaboration March 28, 2023
Details:
The funding will support TB drug discovery, and will allow the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Funding March 24, 2023
Details:
Evotec has significantly scaled up its activities to develop compounds from BMS’s industry-leading library of cereblon E3 ligase modulators and continues to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the field of oncology.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $5,200.0 million Upfront Cash: $200.0 million
Deal Type: Partnership March 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
